Razazian M, Khosravi M, Bahiraii S, Uzan G, Shamdani S, Naserian S. Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells. World J Stem Cells 2021; 13(8): 971-984 [PMID: 34567420 DOI: 10.4252/wjsc.v13.i8.971]
Corresponding Author of This Article
Sina Naserian, PhD, Director, Research Scientist, Institut national de la santé et de la recherche médicale (Inserm) Unité Mixte de Recherche-Inserm-Ministère de la Défense 1197, Hôpital Paul Brousse, Bâtiment Lavoisier, 12-14 avenue Paul Vaillant Couturier, Villejuif 94800, France. sina.naserian@inserm.fr
Research Domain of This Article
Cell Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Aug 26, 2021; 13(8): 971-984 Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.971
Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells
Mehdi Razazian, Maryam Khosravi, Sheyda Bahiraii, Georges Uzan, Sara Shamdani, Sina Naserian
Mehdi Razazian, Georges Uzan, Sara Shamdani, Sina Naserian, Institut national de la santé et de la recherche médicale (Inserm) Unité Mixte de Recherche-Inserm-Ministère de la Défense 1197, Hôpital Paul Brousse, Villejuif 94800, France
Maryam Khosravi, Microenvironment & Immunity Unit, Institut Pasteur, Paris 75724, France
Maryam Khosravi, Institut national de la santé et de la recherche médicale (Inserm) Unit 1224, Paris 75724, France
Sheyda Bahiraii, Department of Pharmacognosy, University of Vienna, Vienna 1090, Austria
Georges Uzan, Sara Shamdani, Sina Naserian, Paris-Saclay University, Villejuif 94800, France
Sara Shamdani, Sina Naserian, CellMedEx; Saint Maur Des Fossés 94100, France
Author contributions: Razazian M and Khosravi M contributed equally in this study; Naserian S conceived the subject and determined the different sections of the manuscript; Razazian M, Khosravi M, Bahiraii S, Shamdani S, and Naserian S wrote the manuscript; Uzan G, Shamdani S, and Naserian S revised the manuscript; All authors read and approved the final manuscript.
Conflict-of-interest statement: Naserian S is the CEO of CellMedEx Company; Naserian S was supported by a governmental grant via ‘’l’Agence Nationale de la Recherche’’ in the form of ‘’programme d'Investissements d’avenir’’, No. ANR_15-RHUS60002; Shamdani S was supported by a grant via ‘’ la Fondation de la Maison de la Chimie’’ for the project R20150LL, No. RAK20150LLA; the rest of the authors declare no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sina Naserian, PhD, Director, Research Scientist, Institut national de la santé et de la recherche médicale (Inserm) Unité Mixte de Recherche-Inserm-Ministère de la Défense 1197, Hôpital Paul Brousse, Bâtiment Lavoisier, 12-14 avenue Paul Vaillant Couturier, Villejuif 94800, France. sina.naserian@inserm.fr
Received: February 24, 2021 Peer-review started: February 24, 2021 First decision: April 20, 2021 Revised: April 28, 2021 Accepted: July 16, 2021 Article in press: July 16, 2021 Published online: August 26, 2021 Processing time: 176 Days and 14.1 Hours
Abstract
Bone-marrow-derived mesenchymal stem cells and endothelial progenitor cells have some interesting biological properties that make them unique for cell therapy of degenerative and cardiovascular disorders. Although both cell populations have been already studied and used for their regenerative potentials, recently their special immunoregulatory features have brought much more attention. Mesenchymal stem cells and endothelial progenitor cells have both proangiogenic functions and have been shown to suppress the immune response, particularly T cell proliferation, activation, and cytokine production. This makes them suitable choices for allogeneic stem cell transplantation. Nevertheless, these two cells do not have equal immunoregulatory activities. Many elements including their extraction sources, age/passage, expression of different markers, secretion of bioactive mediators, and some others could change the efficiency of their immunosuppressive function. However, to our knowledge, no publication has yet compared mesenchymal stem cells and endothelial progenitor cells for their immunological interaction with T cells. This review aims to specifically compare the immunoregulatory effect of these two populations including their T cell suppression, deactivation, cytokine production, and regulatory T cells induction capacities. Moreover, it evaluates the implications of the tumor necrosis factor alpha-tumor necrosis factor receptor 2 axis as an emerging immune checkpoint signaling pathway controlling most of their immunological properties.
Core Tip: This present article aims to review for the first time some known similarities and differences between mesenchymal stem cell and endothelial progenitor cell immunomodulatory functions. It describes and compares different mechanisms that they use to suppress conventional T cells and/or to induce regulatory T cells. Among different mechanisms of action, we emphasize the implication of the immune checkpoint signaling pathways such as the tumor necrosis factor alpha-tumor necrosis factor receptor 2 axis. We try to cover the lack of information by proposing new research paths and their importance for future studies including in vitro and in vivo applications in regenerative medicine.
